Cargando…
Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19
In March 2020, the WHO declared the COVID-19 disease as a pandemic disease. There have been studies on the COVID-19 to find a certain treatment, but yet, there is no certain cure. In this article, we present a possible way to treat severe cases of COVID-19. Based on the previous studies, there are s...
Autores principales: | Sedokani, Amin, Feizollahzadeh, Sadegh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351975/ https://www.ncbi.nlm.nih.gov/pubmed/32753842 http://dx.doi.org/10.2147/DDDT.S262491 |
Ejemplares similares
-
FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody
por: Zhang, Di, et al.
Publicado: (2018) -
Expression and function of FcγRII on NK cells in rhesus macaques
por: He, X, et al.
Publicado: (2012) -
Decreased expression of FcγRII in active Graves' disease patients
por: Lu, Xixuan, et al.
Publicado: (2019) -
The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease
por: Anania, Jessica C., et al.
Publicado: (2019) -
Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules
por: Das, Undurti N
Publicado: (2008)